Analyst Price Target is $8.50
▲ +166.46% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gain Therapeutics in the last 3 months. The average price target is $8.50, with a high forecast of $10.00 and a low forecast of $6.00. The average price target represents a 166.46% upside from the last price of $3.19.
Current Consensus is
Buy
The current consensus among 4 investment analysts is to buy stock in Gain Therapeutics. This Buy consensus rating has held steady for over two years.
Gain Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of allosteric therapies. Its lead drug candidate, GT-02287 for the treatment of GBA1 Parkinson's disease is being evaluated in a Phase 1 clinical trial. Its drug discovery platform Magellan identifies novel allosteric binding sites on disease-implicated proteins and exploits untapped opportunities, by pinpointing pockets that cannot be found or drugged with current technologies. The company's platform is enhanced with new AI and machine-learning tools and virtual screening capabilities to access the emerging on-demand compound libraries covering chemical spaces of approximately 50 billion compounds. It deploys its platform by accelerating drug discovery and unlocking novel disease-modifying treatments for untreatable or difficult-to-treat disorders, including neurodegenerative diseases, rare genetic disorders, and oncology. Gain Therapeutics, Inc. was founded in 2017 and is headquartered in Bethesda, Maryland.
Read More
